Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients

Table 3 Association between unsaturated fatty acids and risk of clinically significant fibrosis in non-alcoholic fatty liver disease

Characteristics	Univariate			Multivariable adjusted
	OR	95%CI	P value	OR	95%CI	P value
ω-3 PUFAs
α-C18:3	1.060	1.015-1.116	0.017a	1.078	1.018-1.153	0.018a
ω-3-C22:5	1.193	0.992-1.446	0.064	1.176	0.930-1.504	0.181
ω-6 PUFA
γ-C18:3	1.409	1.125-1.879	0.009a	1.518	1.135-2.228	0.013a

^aP < 0.05: Statistically significant.

Multivariable adjusted analysis including age, body mass index, sex, systolic blood pressure, duration of diabetes, triglyceride-glucose, hemoglobin A1c, fasting C-Peptide, C-peptide 2 h after meal, uric acid, 8 kinds of hypoglycemic drugs (metformin, acarbose, sulfonylureas, glinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-dependent glucose transporters 2 inhibitors, glucagon-like peptide-1 agonists, and insulin), and Statins. NAFLD: Non-alcoholic fatty liver disease; F_2-4: Fibrosis 4 score ≥ 1.3; OR: Odds ratios; CI: Confidence interval; PUFA: Polyunsaturated fatty acid; TZDs: Thiazolidinediones; DPP-4 inhibitor: Dipeptidyl peptidase-4 inhibitor; SGLT-2 inhibitor: Sodium-dependent glucose transporters 2; GLP-1: Glucagon-like peptide-1.